ArticleLeukemia2025

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.

Tommaso Balestra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.